The C. diff Debate: The Role of Diagnostics in Disease Determination
|
|
- Alexina Chapman
- 6 years ago
- Views:
Transcription
1 The C. diff Debate: The Role of Diagnostics in Disease Determination Saturday Evening June 3, :30 PM ASM Microbe 2017 Bissonet Meeting Room New Orleans Marriott
2 Program Disclosures Planned and developed by Medavera, Inc. and supported by an educational grant from Alere, Inc. This event is neither sponsored nor endorsed by the American Society for Microbiology. 2
3 Agenda 7:30 7:55 PM C. difficile: New Developments and Discoveries Moderator Proposition: NAATs are Best for Determining CDI 7:55 8:10 PM NAATs are the Best Diagnostic Approach to CDI 8:10 8:25 PM NAATs are Not the Best Diagnostic Approach to CDI Ciarán P. Kelly, MD Professor Ferric C. Fang, MD Professor Mark H. Wilcox, MD 8:25 8:30 PM Rebuttal Professor Ferric C. Fang, MD 8:30 8:35 PM Rebuttal Professor Mark H. Wilcox, MD 8:35 8:40 PM Closing Arguments 8:40 8:50 PM Panel Discussion: Arguments For and Against 8:50 9:00 PM Q & A 3
4 Learning Objectives Identify new developments and discoveries with C. difficile Review current guidelines for C. difficile diagnosis and prevention Assess CDI testing methodologies and current controversies Apply findings to determine the appropriate protocol and testing algorithms for CDI for one s institution 4
5 Continuing Education Credits Educational Review Systems is an approved provider by P.A.C.E. This program is approved for 1.5 hours of CE credit. In order to obtain your CE credit, please visit CdiffDebate.com and follow the instructions. 5
6 This program is being audio recorded and will be produced along with the slides into an enduring material which will be available within 3 weeks at CdiffDebate.com For those who were unable to attend this live program, they may apply for P.A.C.E. credits after viewing. Please send an to info@medavera.com if you have questions or need assistance.
7 C. difficile: New Developments and Discoveries Ciarán P. Kelly, MD Professor of Medicine Harvard Medical School Director Gastroenterology Fellowship Training Beth Israel Deaconess Medical Center Boston, Massachusetts
8 Disclosures Ciarán P. Kelly, MD Commercial Interest Relationship Role Actelion Honorarium Consultant GSK Honorarium Consultant Institut Merieux Grant Merck Honorarium, Grant Consultant, Speaker National Institutes of Health, U.S. Grant Seres Therapeutics Honorarium Consultant, Speaker Summit Honorarium Consultant Synthetic Biologics Honorarium Consultant Vedanta Honorarium Consultant 8
9 Setting the Stage Clostridium difficile Infection (CDI) Multiple clinical outcomes An urgent threat in the U.S. Therapies The old The new The future Several diagnostic approaches Find the smoking gun or Catch the bullet? 9
10 C. difficile Infection - Pathogenesis Not always especially community-acquired CDI Antibiotics or Neonate or IBD Antibiotic therapy Disturbed colonic microflora (Loss of colonization resistance) Nosocomial common But spores are ubiquitous Strains differ in virulence C. difficile exposure and colonization Strains are toxinogenic or not Toxin production Anti-toxin immunity is protective Kelly CP, LaMont TJ. N Engl J Med. 2008;359: Kyne L, Warny M, Qamar A, et al. Lancet. 2001;357: Symptomless carriage Diarrhea and colitis 10
11 BIDMC C. difficile Infection Results in Variable Clinical Outcomes Aslam S, Hamill RJ, Musher DM. Lancet Infect Dis. 2005;5:
12 Nosocomial C. difficile Infection and Asymptomatic Carriage Are Common Hospital patients (Acute medical ward) LOS > 2 days Receiving antibiotic 271 enrolled Colonized by C. difficile 84 (31%) Hospital-acquired 47 (17%) Colonized at admission 37 (14%) CDI case 28 (10%) Carrier 19 (7%) CDI case 19 (7%) Carrier 18 (7%) Kyne L, Warny M, Qamar A, et al. N Engl J Med. 2000;342: * In progress study (also at BIDMC, Boston) In 2017, the carrier rate in this population is 10%.* 12
13 C. difficile Toxin Production Does regulation of toxin production determine clinical outcomes? Should we quantify bacterial burden or toxin concentrations? Kelly CP, LaMont TJ. N Engl J Med. 2008;359:
14 Clostridium difficile An Urgent Threat 14
15 Incidence of Both Principal and Secondary CDI Diagnoses Continues to Increase All-Listed Diagnoses Lucado J, Gould C, Elixhauser A. HCUP Statistical Brief # Accessed 5/26/17. 15
16 Estimated No. of CDI Cases Burden of C. difficile Infection in the U.S. (2011) Primary CDI cases in U.S. in 2011 ~480,000 ~2/3 of CDI cases were healthcare associated infections but only ~1/4 were hospitalized when symptoms began Most community-associated CDI cases (82%) appeared to be associated with outpatient healthcare exposures Community-associated CDI Healthcare-associated CDI Leesa FC, Mu Y, Bamberg WM, et al. N Engl J Med. 2015;372(9):
17 % of All HAIs C. difficile Infection Is a Common Cause of Healthcare Associated Infection (HAI) Most Common Healthcare-associated Infections 25% 20% 21.8% 21.8% 17.1% Clostridium difficile was the cause of 70.9% of healthcare-associated gastrointestinal infections 15% 12.9% 10% 9.9% 5% 0% Pneumonia Surgical-Site Infection Gastrointestinal Infection Urinary Tract Infection Primary Bloodstream Infection C. difficile is the most commonly reported specific pathogen causing 12.1% of HAI. Magill SS, Edwards JR, Bamberg W, et al. N Engl J Med. 2014;370(26):
18 Recurrences and Deaths Associated With CDI: Adjusted U.S. National Estimates for 2011 Recurrence Rate Mortality Rate Unmet medical needs in CDI: Mortality Recurrence Definitive diagnosis #1 High Incidence 25% 20% 15% 10% 5% 0% 13.5% CA-CDI 20.9% HA-CDI 10% 9% 8% 7% 6% 5% 4% 3% 2% 1% 0% 1.3% CA-CDI 9.3% HA-CDI 14 through 56 days following initial CDI Within 30-days of the initial positive C. difficile testing results Leesa FC, Mu Y, Bamberg WM, et al. N Engl J Med. 2015;372(9):
19 C. difficile Infection Why the Increasing Incidence, Severity and Recurrence Rates? Host factors Age Immune response Underlying disease Bacterial factors Virulence Sporulation Antibiotic resistance Environment Antibiotic use PPI use Burden of contamination by C. difficile spores Kelly CP, LaMont TJ. N Engl J Med. 2008;359: Bauer MP, Kuijper EJ, van Dissel JT, et al. Clin Microbiol Infect. 2009;15: Cohen SH, Gerding DN, Johnson S, et al. Infect Control Hosp Epidemiol. 2010;31(5):
20 C. difficile Infection Approaches to Therapy Bacteriotherapies e.g. FMT (and FMT refinements), Non-toxinogenic C. difficile Selective anti-c. difficile antibiotics e.g. fidaxomicin, cadazolid, ridinilazole Toxin binders Immune therapies: Passive anti-toxin infusion or active vaccination Kelly CP, LaMont TJ. N Engl J Med. 2008;359: Kyne L, Warny M, Qamar A, et al. Lancet. 2001;357: Antibiotic therapy Disturbed colonic microflora (Loss of colonization resistance) C. difficile exposure and colonization Toxin production Symptomless carriage Diarrhea and colitis 20
21 C. difficile Infection Approaches to Therapy Bacteriotherapies e.g. FMT (and FMT refinements), Non-toxinogenic C. difficile Antibiotic therapy Disturbed colonic microflora (Loss of colonization resistance) C. difficile exposure and colonization Toxin production Kelly CP, LaMont TJ. N Engl J Med. 2008;359: Kyne L, Warny M, Qamar A, et al. Lancet. 2001;357: Symptomless carriage Diarrhea and colitis 21
22 Duodenal Infusion of Donor Feces for Recurrent C. difficile Infection Microbiota Diversity Donors Recipients After Infusion Recipients Before Infusion van Nood E, Vrieze A, Nieuwdorp M, et al. N Engl J Med. 2013;368(5):
23 Non-Toxinogenic C. difficile Spores Nature s Tailor-Made Probiotic? NTCD (Non-toxinogenic C. difficile) Spores of strain VP20621 Protects hamsters against colonization by toxinogenic C. difficile and against CDI Phase II Trail All with CDI or oral vancomycin Placebo (N = 43) NTCD (Total N = 125) 10 4 x 7 days (N = 41) 10 7 x 7 days (N = 43) 10 7 x 14 days (N = 41) P < P < % Recurrence rate in those colonized by NTCD Gerding DN, Meyer T, Lee C, et al. J Am Med Assoc. 2015;313(17):
24 C. difficile Infection Approaches to Therapy Antibiotic therapy Selective anti-c. difficile antibiotics e.g. fidaxomicin, cadazolid, ridinilazole Disturbed colonic microflora (Loss of colonization resistance) C. difficile exposure and colonization Toxin production Kelly CP, LaMont TJ. N Engl J Med. 2008;359: Kyne L, Warny M, Qamar A, et al. Lancet. 2001;357: Symptomless carriage Diarrhea and colitis 24
25 Fidaxomicin vs. Vancomycin for Clostridium difficile Infection Initial Response Recurrence Sustained Response Louie TJ, Miller MA, Mullane KM, et al. N Engl J Med. 2011: 364(5): FDA approved for CDI therapy
26 C. difficile Infection Approaches to Therapy Antibiotic therapy Disturbed colonic microflora (Loss of colonization resistance) Toxin binders C. difficile exposure and colonization Toxin production Kelly CP, LaMont TJ. N Engl J Med. 2008;359: Kyne L, Warny M, Qamar A, et al. Lancet. 2001;357: Symptomless carriage Diarrhea and colitis 26
27 Phase 3 Multicenter Trials of Tolevamer (Oral Toxin-Binding Agent) vs. Metronidazole vs. Vancomycin for CDI * P < 0.001, tolevamer (T) vs. metronidazole (M) and T vs vancomycin (V) ** P = 0.020, M vs. V > 1,000 patients randomized 2:1:1 to T, M, & V between 2005 & 2007 Johnson S, Louie TJ, Gerding DN, et al. Clin Infect Dis. 2014;59:
28 C. difficile Infection Approaches to Therapy Antibiotic therapy Disturbed colonic microflora (Loss of colonization resistance) C. difficile exposure and colonization Immune therapies: Passive anti-toxin infusion or active vaccination Kelly CP, LaMont TJ. N Engl J Med. 2008;359: Kyne L, Warny M, Qamar A, et al. Lancet. 2001;357: Toxin production Symptomless carriage Diarrhea and colitis 28
29 Bezlotoxumab (Neutralizing Anti-Toxin B IgG HuMab) Infusion During Standard of Care CDI Therapy Reduces Later CDI Recurrence Reduction in CDI recurrence: Absolute: 10% Relative: 37% Wilcox MH, Gerding DN, Poxton IR, et al. N Engl J Med. 2017;376(4):
30 Antitoxin Immunization to Break the Cycle of Dysbiosis in Recurrent C. difficile Infection Antibiotic therapy Disturbed Restored colonic colonic microflora microflora (Loss of colonization resistance) (return of colonization resistance) X Recurrence Passive anti-toxin immunotherapy C. difficile exposure and colonization Kelly CP, LaMont TJ. N Engl J Med. 2008;359: Kyne L, Warny M, Qamar A, et al. Lancet. 2001;357: Toxin production X Symptomless carriage Diarrhea and colitis X X Dysbiosis Antibiotic treatment X 30
31 Diagnostic Tests May Detect Spores, Vegetative Forms, and/or Toxins Phase Spore Vegetative Toxin producing and releasing Detection assay Culture NAAT (e.g. PCR) Culture NAAT (e.g. PCR) GDH (Glutamate DeHydrogenase) Tissue culture cytotoxicity Enzyme immunoassay (EIA) New ultra sensitive & quantitative EIAs 31
32 CDI Diagnostics Debate CDI is a very common HAI - a growing and urgent threat Colonization by toxinogenic C. difficile may be fatal or symptomless Hence any stool test result must be interpreted in the context of the clinical picture Question: Which approach to stool testing for CDI is best? Find: The smoking gun (toxinogenic organism) or The bullet (toxins) Without accurate and clinically meaningful diagnostics our current or newer, more effective but also more expensive, therapies cannot be employed effectively Aslam S, Hamill RJ, Musher DM. Lancet Infect Dis. 2005;5:
33 The C. diff Debate: The Role of Diagnostics in Disease Determination Saturday Evening June 3, :30 PM ASM Microbe 2017 Bissonet Meeting Room New Orleans Marriott
34 NAATs Are the Best Diagnostic Approach for Clostridium difficile Infections Ferric C. Fang, MD Professor of Laboratory Medicine and Microbiology Adjunct Professor of Medicine (Infectious Diseases) Director, Harborview Medical Prof. Center Ferric Clinical C. Fang Microbiology Laboratory University of Washington School School of Medicine of Medicine Seattle, Seattle, Washington, Washington USA
35 Disclosures Ferric C. Fang, MD Commercial Interest Relationship Role Biofire Honorarium, Reagents Consultant, Speaker, Researcher Cepheid Honorarium Consultant, Speaker 35
36 A True Statement About C. difficile A. Patients with positive nucleic acid amplification test (NAAT) and negative toxin EIA assays are merely colonized. B. Glutamate dehydrogenase (GDH) is as sensitive as NAAT and can be used as a cost-effective screening test. C. Patients with C. difficile diarrhea have higher toxin levels than those who are asymptomatically colonized. D. Patients with C. difficile diarrhea have higher organism burdens than those who are asymptomatically colonized. E. All of the above. F. None of the above. 36
37 A True Statement About C. difficile A. Patients with positive nucleic acid amplification test (NAAT) and negative toxin EIA assays are merely colonized. B. Glutamate dehydrogenase (GDH) is as sensitive as NAAT and can be used as a cost-effective screening test. C. Patients with C. difficile diarrhea have higher toxin levels than those who are asymptomatically colonized. D. Patients with C. difficile diarrhea have higher organism burdens than those who are asymptomatically colonized. E. All of the above. F. None of the above. 37
38 C. difficile Infection (CDI) Is Caused by Toxins REF: Kelly and Lamont. New Engl J Med,
39 Percent The Presence of Toxigenic C. difficile or Toxin Is Necessary but Not Sufficient for Disease Toxigenic Cx Toxin Asymptomatic (65) Diarrhea (31) Colitis (3) McFarland LV, Elmer GW, Stamm WE, et al. Infect Immun. 1991;
40 Cytotoxin Assays Are Insensitive for CDI N Toxin Toxigenic Cx Reference % 98% Arch Intern Med. 1986;146: % 97% Diagn Micro Infect Dis. 1988;10: % 92% Infect Immun. 1991;59: % 93% J Clin Microbiol. 1992;30: % 100% Eur J Clin Microbiol Infect Dis. 1992;11: % ND Ann Intern Med. 1995;123: % 95% J Clin Microbiol. 1996;34: % 100% Pathol Biol. 1999;47; % 100% J Hosp Infect. 2001;48: % 94% J Clin Microbiol. 2001;39:
41 Enzyme Immunoassays Are Less Sensitive Than Tissue Culture Cytotoxin Assays Peterson LR, Kelly PJ. Infect Dis Clin North Am. 1993;7(2):
42 NAAT Sensitivity Is Comparable to Toxigenic Culture Direct Culture (No. of Samples) Enrichment Culture (No. of Samples) NAAT Positive Negative Total Positive Negative Total Positive Negative Total In a prospective, multicenter trial, NAAT was 99% sensitive and 91% specific compared with direct culture. Tenover FC, Novak-Weekley S, Woods CW, et al. J Clin Microbiol. 2010;48(10):
43 NAAT Is More Sensitive Than EIA/Cytotoxin Assays Site No. Site Assay N Sensitivity (%) NAAT Site 1 Toxin A/B EIA GDH-EIA Toxin A/B EIA Toxin A/B EIA GDH-EIA-PCR Toxin A/B EIA Cytotoxin Tenover FC, Novak-Weekley S, Woods CW, et al. J Clin Microbiol. 2010;48(10):
44 NAAT Is the Most Cost-Effective Diagnostic Strategy for C. difficile 2-Step GDH Algorithm NAAT Schroeder LF, Robilotti E, Peterson LR, et al. J Clin Microbiol. 2014;52(2):
45 GDH Sensitivity Is Strain-Dependent Sensitivity (%) P-Value Ribotype N C. difficile PCR NAAT GDHbased Algorithms Non % Tenover FC, Novak-Weekley S, Woods CW, et al. J Clin Microbiol. 2010;48(10):
46 Fecal Toxin Assays Cannot Distinguish Asymptomatic Carriage and CDI Significant Diarrhea No Significant Diarrhea Significant Diarrhea No Significant Diarrhea Anikst VE, Gaur RL, Schroeder LF, et al. Diagn Microbiol Infect Dis. 2016;84(4):
47 Organism Load Cannot Distinguish Asymptomatic Carriage and CDI Anikst VE, Gaur RL, Schroeder LF, et al. Diagn Microbiol Infect Dis. 2016;84(4):
48 A Negative Cytotoxin Assay Cannot Rule Out CDI 48
49 Percent Response Toxin+ and Toxin- Patients Respond Similarly to CDI Treatment 100 Vancomycin Placebo NA Cx+ Tox+ Cx+ Tox- Cx- Tox- Keighley MR, Burdon DW, Arabi Y, et al. Br Med J. 1978;2(6153):
50 Cytotoxin Assays Can Be Negative Even in Severe CDI Fulminant CDI had a 70% mortality. 12.5% had negative toxin assays Patients diagnosed at autopsy were twice as likely to have a false-negative toxin assay. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Ann Surg ;235(3):
51 NAAT Reduces Empiric Antibiotic Treatment of C. difficile Clinical and economic outcomes EIA (n = 79) NAAT (n = 87) P Duration of antibiotic therapy in days, mean (CI) 2.31 ( ) 0.88 ( ) Diagnostic test performed per patient, mean (CI) 2.73 ( ) 1.16 ( ) <0.001 Duration of contact insolation in days, mean (CI) 1.46 ( ) 0.62 ( ) Total treatment cost per patient 1 (CI) ( ) ( ) Diagnostic test cost ( ) ( ) <0.001 Antibiotic therapy cost 1 (CI) ( ) ( ) Contact isolation cost 1 (CI) ( ) 8.19 ( ) Antimicrobial prescribing EIA (n = 79) (n = 87) P Doses administered, mean (CI) 7.24 ( ) 3.91 ( ) No treatment, n (%) 54 (68.4) 71 (81.6) Metronidazole monotherapy, n (%) 16 (20.2) 11 (12.6) Vancomycin monotherapy, n (%) 7 (8.9) 3 (3.5) Combination therapy, n (%) 2 (2.5) 2 (2.3) Peppard WJ, Ledeboer NA. Hosp Pharm. 2014;49(7):
52 Switching From EIA to NAAT May Result in Reduced Length-of-Stay The impact of PCR on Clostridium difficile detection and clinical outcomes Mona Akbari, Alina Vodonos, George Silva, Manida Wungjiranirun, Daniel A. Leffler, Ciarán P. Kelly and Victor Novak Characteristic EIA NAAT P value Gender [n (%)] Female 1125 (52.0%) 153 (56.46%) Male 1038 (48.0%) 118 (43.54%) Abdominal pain [n (%)] No 2138 (98.84%) 258 (95.20%) <0.001 Yes 25 (1.16%) 13 (4.80%) Age [mean ± SD] 67 ± ± BUN [(mg dl 1 ) mean ± SD] ± ± Cr [(mg dl 1 ) mean ± SD] 1.64 ± ± Albumin [(g dl 1 ) mean ± SD] 3.09 ± ± WBC [(x 10 3 cells µl 1 ) mean ± SD] ± ± Hgb [(g dl 1 ) mean ± SD] ± ± Hct [(%) mean ± SD] ± ± Na [(meq dl 1 ) mean ± SD] ± ± HCO 3 [(meq dl 1 ) mean ± SD] ± ± Median length of stay [days (range)] 10 (3 146) 8 (3 151) Akbari M, Vodonos A, Silva G, et al. J Med Microbiol. 2015;64(9):
53 Number of Cases C. difficile NAAT Can Facilitate Infection Control Cases Rate NAAT Year Unpublished internal institutional data. Rate per 1000 Patient-Days 53
54 C. difficile Diagnostic Algorithms > 3 soft/liquid stools in 24 hours GDH Immunoassay Toxin Immunoassay Insensitive GDH Immunoassay NAAT Toxin Immunoassay Toxin Immunoassay Potential Underdiagnosis NAAT Potential Overdiagnosis NAAT Unpublished from various laboratories. Moderately Sensitive Potential Overdiagnosis Complex Reporting 54
55 Conclusions CDI requires a toxigenic organism and a susceptible host diagnostic assays must be interpreted in clinical context Two-step algorithms (GDH/NAAT) are less expensive but also less sensitive and increase the complexity of reporting NAATs are rapid, cost-effective, and sensitive, and facilitate effective infection control and stewardship Overdiagnosis can be minimized by limiting testing to patients with clinical presentations consistent with CDI Reliance on toxin assays can result in underdiagnosis, including some patients with severe and even life-threatening infections 55
56 Fast is fine, but accuracy is everything. Wyatt Earp 56
57 NAATs Are Not the Best Diagnostic Approach to CDI Professor Mark Wilcox, MD Leeds Teaching Hospitals & University of Leeds, UK Public Health England Size matters!
58 Disclosures Mark H. Wilcox, MD Commercial Interest Relationship Role Abbott Honorarium Consultant, Speaker Actelion Honorarium Consultant, Speaker Astellas Honorarium Consultant, Speaker Biomerieux Honorarium Consultant, Speaker Cubist Honorarium Consultant, Speaker Da Volterra Honorarium Consultant, Speaker European Tissue Symposium Honorarium Consultant, Speaker Optimer Honorarium Consultant, Speaker Pfizer Honorarium Consultant, Speaker Qiagen Honorarium Consultant, Speaker Sanofi Pasteur Honorarium Consultant, Speaker Summit Honorarium Consultant, Speaker Alere Honorarium Consultant Basilea Pharmaceutica Honorarium Consultant Durata Therapeutics Honorarium Consultant Merck Honorarium Consultant Nabriva Therapeutics Honorarium Consultant
59 Size Matters The size of the population at risk of Clostridium difficile infection (CDI) The size of the overlap between CDI and non-cdi cases The size of the CDI diagnosis error rate The size of the consequences of erroneous CDI testing The true size of the CDI challenge 59
60 Size Matters The size of the population at risk of Clostridium difficile infection (CDI) The size of the overlap between CDI and non-cdi cases The size of the CDI diagnosis error rate The size of the consequences of erroneous CDI testing The true size of the CDI challenge 60
61 Common Causes of Diarrhoea Infectious Clostridium difficile Norovirus Other viruses: rotavirus, adenovirus Other bacteria: Salmonella, Campylobacter, Shigella, Escherichia coli Non-infectious Inflammatory bowel disease Gastrointestinal neoplasia Irritable bowel syndrome Celiac disease Anxiety Food allergy Lactose intolerance Iatrogenic Use of laxatives Nasogastric feeding Post-gastrointestinal surgery Radiotherapy Antibiotic-assoc. diarrhoea (non-infective) Other drugs: selective serotonin reuptake inhibitors, NSAIDs, statins 61
62 Common Causes of Diarrhoea Infectious Clostridium difficile Norovirus Other viruses: rotavirus, adenovirus Other bacteria: Salmonella, Campylobacter, Shigella, Escherichia coli Non-infectious Inflammatory bowel disease Gastrointestinal neoplasia Irritable bowel syndrome Celiac disease Anxiety Food allergy Lactose intolerance Iatrogenic Use of laxatives Nasogastric feeding Post-gastrointestinal surgery Radiotherapy Antibiotic-assoc. diarrhoea (non-infective) Other drugs: selective serotonin reuptake inhibitors, NSAIDs, statins 62
63 63
64 Day Prevalence of Hospital Onset Diarrhoea (HOD) (N = 4,995 Patients on 141 Wards in 32 Hospitals) Hospital type HOD point prevalence 95% C.I. All 4.6% % Non-teaching 2.9% % Specialty 10.0% % Teaching 6.1% % HOD: 2 episodes of Bristol Stool Type 5-7 in 24 hours before evaluation day; onset > 48 hours after admission. Mawer D et al. ECCMID Abstract OS
65 Size Matters The size of the population at risk of CDI The size of the overlap between CDI and non-cdi cases The size of the CDI diagnosis error rate The size of the consequences of erroneous CDI testing The true size of the CDI challenge 65
66 Hospital Onset Diarrhoea Patients: Key Messages HOD patients were elderly (median age 77) Hospitalised for a median 8 days before diarrhoea onset A quarter had 1 previous HOD episodes that admission 85% had multiple possible causes (range 2-13) 54% were receiving antimicrobials 85% were taking other medication that can cause diarrhoea No difference in the number of potential causes of HOD per patient between those tested for CDI vs. not tested vs. CDI (median 3 per group; P = 0.55) 66
67 Size Matters The size of the population at risk of CDI The size of the overlap between CDI and non-cdi cases The size of the CDI diagnosis error rate The size of the consequences of erroneous CDI testing The true size of the CDI challenge 67
68 The Wrong Interpretation of The More You Test, the More You Find We introduced PCR testing and our CDI rate went up. No, it didn t. The CDI rate stayed the same; you just issued more positive results. 68
69 Setting CDI Test Change Inflation of CDI Reported Rate 3 states in CDC s Emerging Infections Program CDI surveillance EIA PCR 43% - 67% Multi-hospital EIA PCR 56% Single center EIA PCR 57% Single center EIA PCR 110% Single center GDH + EIA + CCNA PCR 50% Single center EIA GDH + PCR 97% Single center GDH + EIA GDH + EIA + PCR 70% EIA: enzyme immunoassay; PCR: polymerase chain reaction; GDH: glutamate dehydrogenase; CCNA: cell cytotoxicity neutralization assay Gould CV, Edwards JR, Cohen J, et al. Clin Infect Dis. 2013;57(9): Moehring RW, Lofgren ET, Anderson DJ. Infect Control Hosp Epidemiol. 2013;34: Goldenberg SD. Infect Control Hosp Epidemiol. 2011;32: Williamson DA, Basu I, Freeman J, et al. Am J Infect Control. 2012;41: Longtin Y, Trottier S, Brochu G, et al. Clin Infect Dis. 2013;56(1): de Jong E, de Jong AS, Bartels CJ, et al. Eur J Clin Microbiol Infect Dis. 2012;31: Fong KS, Fatica C, Hall G, et al. Infect Control Hosp Epidemiol. 2011;32:
70 12,240 samples analyzed from 10,691 episodes 12,186 patients 8,026 in-patient results from 6,665 episodes 6,355 in-patients Outcome results available for 6,522 inpatient episodes 435 cell cytotoxin assay (CTA) positive 207 cytotoxigenic culture (CC) positive and negative 5,880 both CC and CTA negative 5,927 patients survived, 595 patients died Planche TD, Davies KA, Coen PG, et al. Lancet Infect Dis. 2013;13:
71 41% Increase Cytotoxin +ve (731, 5.9%) Cytotoxigenic culture +ve (1030, 8.3%) Toxin +ve NAAT +ve, Toxin -ve NAAT -ve, Toxin -ve WCC x 10 9 /L 12.4 a 9.9 a 10.0 Death by day 30 72/435 (16.6%) b 30/311 (9.7%) b 349/3943 (8.9%) 81% Increase (95% CI: 77-85) NAAT +ve (10.7%) a P < b P = NAAT: nucleic acid amplification test Planche TD, Davies KA, Coen PG, et al. Lancet Infect Dis. 2013;13:
72 Impact of C. difficile Testing Method on Accuracy of Diagnosis 1321 stool samples were tested during 95,750 patient-days 85 hospital associated-cdi cases detected by PCR 56 cases by EIA/CCA (P = 0.01) Overall incidence rate was 8.9 per 10,000 patient-days (95% CI, ) by PCR; 5.8 per 10,000 patient-days (95% CI, ) by EIA/CCA P = 0.001; 53% higher by PCR Overall complication rate was 27% (23/85) when CDI was diagnosed by PCR 39% (22/56) by EIA/CCA (P = 0.16) Cases detected by PCR only were MORE THAN 10x less likely to develop a complication of CDI compared with cases detected by both PCR and EIA/CCA (3% vs. 39%; P < 0.001) Longtin Y, Trottier S, Brochu G, et al. Clin Infect Dis. 2013;56:
73 Outcomes by C. difficile Test Group Outcome C. difficile Positive C. difficile Negative Tox+/PCR+ (N = 131) Tox-/PCR+ (N = 162) C. difficile-related Complication or Death Within 30 d, No. (%) a P-value for significance across 3 groups. b Intensive care unit care, colectomy, or megacolon related to CDI. c All-cause mortality within 30 days was 10.7%, 14.2%, & 8.7%, respectively, for the 3 groups. Tox-/PCR- (N = 1123) P-Value a Complication b 10 (7.6) 0 3 (0.3) < Death c 11 (8.4) 1 (0.6) 0 < Complication or death 18 (13.7) 1 (0.6) 3 (0.3) < Polage CR, Gyorke CE, Kennedy MA, et al. JAMA Intern Med. 2015;175:
74 Size Matters The size of the population at risk of CDI The size of the overlap between CDI and non-cdi cases The size of the CDI diagnosis error rate The size of the consequences of erroneous CDI testing The true size of the CDI challenge 74
75 Incorrect CDI Diagnosis Is a Global Issue Incorrect diagnosis of Clostridium difficile infection in a university hospital in Japan. Mori N, Yoshizawa S, Saga T, et al. J Infect Chemother. 2015;21: Wilcox, et al. ECCMID P1341. U.S. CDI burden 2011: 453, ,300 (no NAAT); 701,000 (all NAAT) Lessa FC, Mu Y, Bamberg W, et al. N Engl J Med. 2015;372:
76 Investigation Summary: C. difficile Diagnosis Analysis was conducted to evaluate both the role of C. difficile diagnostic testing in defining the correct SER-109 Phase 2 study entry population, and in the proper diagnosis of C. difficile recurrences during the study. In the Phase 2 study, 81% of study subjects (72 of 89 subjects) were enrolled based on polymerase chain reaction (PCR) based testing for C. difficile, as well as clinical evaluation. An important and increasingly well-appreciated limitation of PCR testing is that while a positive result indicates that C. difficile cytotoxin genes are present, a positive PCR test does not necessarily indicate thatthe organism is viable and producing disease causing cytotoxins, nor that C. difficile is the source of clinical symptoms. 1 Two separate observations were made pertaining to the effects of discordant results from PCR and cytotoxin assay on the SER- 109 trial. The qualifying stool samples evaluated for Phase 2 study entry were not available for retesting for cytotoxin, however, the company was able to retest the samples associated with patients entering the open label extension trial for the presence of the C. difficile cytotoxin and determined that only 44% of samples (15 of 31 subjects) that tested positive by PCR testing also tested positive based on C. difficile cytotoxin assay. These results suggest that a substantial proportion of patients who entered the SER-109 Phase 2 study may have been C. difficile carriers and, therefore, C. difficile infection may not have been the source of the clinical symptoms. In addition, data from this analysis suggest that the use of PCR to measure C. difficile may have overestimated study recurrences in both treatment arms of the Phase 2 trial, further complicating interpretation of study results. This was shown by reanalysis of samples with cytotoxin assay, from patients diagnosed as recurrent in the Phase 2 study. In this retesting, between one quarter andone half of presumed study recurrences may not have been true C. difficile infections leading to pathology. 76
77 Size Matters The size of the population at risk of CDI The size of the overlap between CDI and non-cdi cases The size of the CDI diagnosis error rate The size of the consequences of erroneous CDI testing The true size of the CDI challenge 77
78 U.S. Clostridium difficile Infection Burden (2011) Lessa FC, Mu Y, Bamberg W, et al. N Engl J Med. 2015;372:
79 NHSN CDI Risk Adjusted SIR Calculation: Determining the Expected Number of CDI LabID Events Dudeck MA, Weiner LM, Malpiedi PJ, et al. Risk Adjustment for Healthcare Facility-Onset C. difficile and MRSA Bacteremia Laboratory-identified Event Reporting in NHSN. Accessed 5/16/17. 79
80 80
81 Two Stage Testing Best of Both Worlds Best for sensitivity GDH or NAAT Best for specificity toxin Most patients get ONE test Identify potential C. difficile excretors cross infection risk Reduce risk of patients being labelled as CDI when they are not Reduce unnecessary treatment of C. difficile colonised patients Reduce inflated CDI rates UK: toxin testing; stage testing; 80% fall in CDI rates 81
82 Size Matters The size of the population at risk of CDI substantial The size of the overlap between CDI and non-cdi cases substantial The size of the CDI diagnosis error rate substantial The size of the consequences of erroneous CDI testing clear & far-reaching The true size of the CDI challenge large challenge without inflation 82
83 The C. diff Debate: The Role of Diagnostics in Disease Determination Saturday Evening June 3, :30 PM ASM Microbe 2017 Bissonet Meeting Room New Orleans Marriott
84 Q & A
85 This program was audio recorded and will be produced along with the slides into an enduring material which will be available within 3 weeks at CdiffDebate.com For those who were unable to attend this live program, they may apply for P.A.C.E. credits after viewing. Please send an to info@medavera.com if you have questions or need assistance.
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationDUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News. Volume 3, Number 6, June 2015
DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News Volume 3, Number 6, June 2015 Diagnostic Testing for Clostridium difficile Infection Background Clostridium difficile
More informationPros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection
Pros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection Christopher R. Polage, MD, MAS Associate Professor of Pathology and Infectious Diseases UC Davis Disclosures Test materials
More informationClostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationOvercoming barriers to effective recognition and diagnosis of Clostridium difficile infection
REVIEW 10.1111/1469-0691.12057 Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection M. H. Wilcox Department of Microbiology, Old Medical School, Leeds Teaching
More informationClostridium difficile Infection (CDI) Guideline Update:
Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH A Webinar for HealthTrust Members Professor of Medicine September 24,
More informationL. Clifford McDonald, MD. Senior Advisor for Science and Integrity September 16, 2015
Controversies and Current Issues in Diagnosis, Surveillance, and Treatment of Clostridium difficile infeciton L. Clifford McDonald, MD Senior Advisor for Science and Integrity September 16, 2015 Division
More informationLe infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo
Le infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo Istituto Nazionale per le Malattie Infettive «lazzaro Spallanzani», IRCCS-Roma The infectious cycle of transmission
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More informationLong-Term Care Updates
Long-Term Care Updates April 2017 Bezlotoxumab to Prevent Recurrent Infection By Amy Wilson, PharmD and Zara Risoldi Cochrane, PharmD, MS, FASCP Introduction The Gram-positive bacteria is a common cause
More informationClostridium difficile infection (CDI) Week 52 (Ending 30/12/2017)
Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) What is Clostridium difficile? Clostridium difficile is a Gram-positive anaerobic spore forming bacillus. It is ubiquitous in nature and
More informationCDI Burden and Pathophysiology
CDI Burden and Pathophysiology Ciarán P. Kelly, MD Professor of Medicine Harvard Medical School Director Gastroenterology Fellowship Training Director Celiac Center Beth Israel Deaconess Medical Center
More informationACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,
More informationNicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma. L infezione da C difficile grave o complicata
Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma L infezione da C difficile grave o complicata Bagdasarian N et al. JAMA 2015; 313: 398-408 European Society
More informationClostridium Difficile colitismore
Clostridium Difficile colitismore virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis
More informationPrevention of Cdiff recurrence: Evidence from a Cdiff Antitoxin
Prevention of Cdiff recurrence: Evidence from a Cdiff Antitoxin Prof. Emilio Bouza Departament of Medicine. Hospital Gregorio Marañon and Complutense University. Madrid. Spain Disclosures Last year Participation
More informationTITLE OF PRESENTATION
TITLE OF PRESENTATION Can C. Subtitle difficile of Infection Presentation Rates Be Used to Judge Prevention Success for Hospitals? David P. Calfee, MD, MS Associate Professor of Medicine and Public Health
More informationLong-Term Care Updates
Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationC. DIFF QUIK CHEK COMPLETE. Get the complete diagnostic picture with just one test. TAP HERE TO SEE THE NEXT PAGE
C. DIFF QUIK CHEK COMPLETE Get the complete diagnostic picture with just one test. TAP HERE TO SEE THE PAGE CLINICIAN Would actionable C. difficile test results in less than 30 minutes improve patient
More informationClostridium difficile infection surveillance: Applying the case definition
Clostridium difficile infection surveillance: Applying the case definition PICNet Conference March 3 rd 2016 Presented by: Tara Leigh Donovan, MSc Managing Consultant (Former Epidemiologist) 1 Disclaimer
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationCorporate Medical Policy Fecal Microbiota Transplantation
Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More informationObjectives Clostridium difficile Infections, So Many Tests, Which One to Choose?
Objectives Clostridium difficile Infections, So Many Tests, Which One to Choose? March 9, 0 http://www.slh.wisc.edu/outreach-data/event-detail.php?id=03 Raymond P. Podzorski, Ph.D., D(ABMM) Clinical Microbiologist
More informationClostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018
Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile
More informationThe Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH
The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick
More informationSerious MRSA infection: anything new?
Serious MRSA infection: anything new? Professor Mark H. Wilcox Leeds Teaching Hospitals & University of Leeds, UK Public Health England & NHS Improvement Potential Conflicts of Interest I have received:
More informationClostridium difficile: An Overview
Clostridium difficile: An Overview CDI Webinar July 11, 2017 PUBLIC HEALTH DIVISION Acute and Communicable Disease Prevention Section Outline Background Microbiology Burden Pathogenesis Diagnostic testing
More informationClostridium difficile Diagnostic and Clinical Challenges
Papers in Press. Published December 11, 2015 as doi:10.1373/clinchem.2015.243717 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2015.243717 Clinical Chemistry 62:2 000 000
More informationHistorical Perspective
The Diagnosis of C. difficile Infections: Does Molecular Make it More or Less difficile? Stephen M. Brecher Ph.D. VA Boston Health Care System BU School of Medicine The opinions expressed in this presentation
More informationManaging Clostridium Difficile: An Old Bug With
932 The Red Section see related editorial on page x Managing Clostridium Difficile: An Old Bug With New Tricks Stephen M. Vindigni, MD, MPH 1,2 and Christina M. Surawicz, MD 1 Am J Gastroenterol (2018)
More informationUpdate on Clostridium difficile infection.
Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible
More information3/23/2012. Impact of Laboratory Testing on Detection and Treatment of Healthcare Associated Infection: The Case of CDI
Impact of Laboratory Testing on Detection and Treatment of Healthcare Associated Infection: The Case of CDI L. Clifford McDonald, MD Lance R. Peterson, MD March 27, 2012 1 Potential COI L. Clifford McDonald,
More informationClostridium difficile (C difficile)
Patient Knowledge and Attitudes About for Clostridium difficile Infection Colin Goodman, MD; Nicholas O Rourke, PharmD; Carla Amundson, MA; and Dimitri Drekonja, MD, MS In a survey of patients with Clostridium
More informationStar Articles in Review
Star Articles in Review CDDW/CASL Meeting Toronto, February 10, 2014 Christina M. Surawicz, MD MACG Professor of Medicine Division of Gastroenterology Department of Medicine University of Washington Disclosure
More informationFecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations Gerhard Rogler,
More informationDoes Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
ISPUB.COM The Internet Journal of Infectious Diseases Volume 15 Number 1 Does Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationDETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE Policy Number: PDS 021 Effective Date:
More informationLos Angeles County Department of Public Health: Your Partner in CDI Prevention
Los Angeles County Department of Public Health: Your Partner in CDI Prevention Dawn Terashita, MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health dterashita@ph.lacounty.gov
More informationCan We Prevent All Healthcare- Associated Clostridium difficile infections in 10 Years?
Can We Prevent All Healthcare- Associated Clostridium difficile infections in 10 Years? Curtis Donskey, M.D. Louis Stokes VA Medical Center Cleveland, Ohio Research support: Clorox, EcoLab, GOJO, Merck,
More informationClinical Infectious Diseases Advance Access published December 7, 2012
Clinical Infectious Diseases Advance Access published December 7, 2012 1 Physician Attitudes Towards the Use of Fecal Transplantation for Recurrent Clostridium Difficile Infection in a Large Metropolitan
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More information500,000 29,000. New 2015 Data. Lessa et al, N Eng J Med 2015: 34.2% of CDI cases were considered community-acquired
Cost-effective Treatment of Clostridium difficile Infection in the ICU Kevin W. Garey, PharmD, MS. Professor and Chair University of Houston College of Pharmacy New 2015 Data 500,000 29,000 Lessa et al,
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationZinplava. (bezlotoxumab) New Product Slideshow
Zinplava (bezlotoxumab) New Product Slideshow Introduction Brand name: Zinplava Generic name: Bezlotoxumab Pharmacological class: Human IgG1 monoclonal antibody Strength and Formulation: 25mg/mL; solution
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationWhat s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington
What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed
More informationAntibiotic treatment comparison in patients with diarrhea
Original Research Article Antibiotic treatment comparison in patients with diarrhea Deva Lal Kast * Senior Consultant Physician, Department of General Medicine, Krishna Hospital, Ex senior Specialist and
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More informationClostridium difficile
Clostridium difficile Sarah Doernberg, MD, MAS Assistant Professor, University of California, San Francisco Medical Director, Adult Antimicrobial Stewardship Disclosures: Consultant for Actelion, prior
More informationDuodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience
Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Benoit Guery Unité des Maladies Infectieuses CHRU - Faculté de Médecine Lille Conflicts of interest Conferences,
More informationTerapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco
Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate
More informationClostridium difficile: Can you smell the new updates?
Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize
More informationBezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital
Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital Objectives Review pathophysiology, risk factors, prevention, and treatment options of
More informationThe Bristol Stool Scale and Its Relationship to Clostridium difficile Infection
JCM Accepts, published online ahead of print on 16 July 2014 J. Clin. Microbiol. doi:10.1128/jcm.01303-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 The Bristol Stool Scale
More informationVirtual Lectures Planning Committee Disclosure Summary
Mayo Medical Laboratories Virtual Lectures 2014 MFMER Virtual Lectures Planning Committee Disclosure Summary As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CPD) must
More informationPatient presentation
Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine
More informationClinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile
https://doi.org/10.1186/s12941-017-0252-7 Annals of Clinical Microbiology and Antimicrobials RESEARCH Open Access Clinical and economic impact of the introduction of a nucleic acid amplification assay
More informationClinical. Clostridium Difficile: Standard Operating Procedure. Document Control Summary. Contents
Clinical Clostridium Difficile: Standard Operating Procedure Document Control Summary Status: Version: Author/Title: Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationThis is a repository copy of Point-Counterpoint: What is the optimal approach for detection of Clostridium difficile infection?.
This is a repository copy of Point-Counterpoint: What is the optimal approach for detection of Clostridium difficile infection?. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/111867/
More informationArticles. Funding Department of Health and Health Protection Agency, UK.
Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection Timothy D Planche, Kerrie A Davies, Pietro G Coen,
More informationNew approaches to treating Clostridium difficile Infection
7:45 8:45 am New Approaches to Treating C. difficile Infection SPEAKER Fred A. Lopez, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Fred A. Lopez,
More informationQuestions and answers about the laboratory diagnosis of Clostridium difficile infection (CDI)
Questions and answers about the laboratory diagnosis of Clostridium difficile infection (CDI) The NHS Centre for Evidence based Purchasing (CEP) has published the results of an evaluation of the performance
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More information6/14/2012. Welcome! PRESENTATION OUTLINE CLOSTRIDIUM DIFFICILE PREVENTION. Teaming Up to Prevent Infections! 1) Impact. 2) Testing Recommendations
CLOSTRIDIUM DIFFICILE PREVENTION Beth Goodall, RN, BSN Board Certified in Infection Prevention and Control DCH Health System Epidemiology Director Welcome! Teaming Up to Prevent Infections! CLOSTRIDIUM
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationClostridium difficile Asymptomatic Carriers The Hidden Part of the Iceberg?
Clostridium difficile Asymptomatic Carriers The Hidden Part of the Iceberg? Disclosures Merck Canada, BD Diagnostics, AMD Medical, Canadian Institute for Health Research Merck Canada, Pfizer OBJECTIVES
More informationCLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT. Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates
CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates Learning Objectives Recognize patients who are highest risk for C. diff infections
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationCan a toxin gene NAAT be used to predict toxin EIA and the severity of Clostridium difficile infection?
Garvey et al. Antimicrobial Resistance and Infection Control (2017) 6:127 DOI 10.1186/s13756-017-0283-z RESEARCH Can a toxin gene NAAT be used to predict toxin EIA and the severity of Clostridium difficile
More informationOngoing Developments in Management of Clostridium difficile Infection
Ongoing Developments in Management of Clostridium difficile Infection Infectious Diseases Spring Symposium Creighton University School of Medicine April 28, 2018, Omaha, NB Stuart Johnson, MD Loyola U.
More informationClostridium difficile infections and fecal transplant
Objectives Clostridium difficile infections and fecal transplant Recognize patients at risk for C. difficile infection (CDI) Contrast diagnostic testing for CDI Describe treatment strategies for mild,
More informationC. Difficile Testing Protocol
C. Difficile Testing Protocol Caroline Donovan, RN, BSN, ONC- Infection Control Practitioner Abegail Pangan, RN, MSN, CIC- Infection Control Practitioner U.S. NEWS & WORLD REPORT 2017 2018 RANKINGS Acute
More informationCDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers
Disclosures No conflict of interest to declare Acknowledgments Objectives and Agenda Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Guidelines
More informationClostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011
Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast
More informationReference assays for Clostridium difficile infection: one or two gold standards?
1 Centre for Infection, Division of Cellular and Molecular Medicine, St George s University of London, Cranmer Terrace, London, UK 2 Microbiology, Leeds Teaching Hospitals and University of Leeds, Old
More informationWhite Rose Research Online URL for this paper:
This is an author produced version of Efficacy of vancomycin extended dosing regimens for treatment of simulated Clostridium difficile infection (CDI) within an in vitro human gut model. White Rose Research
More informationIntroduction ORIGINAL ARTICLE
Eur J Clin Microbiol Infect Dis (2016) 35:251 259 DOI 10.1007/s10096-015-2538-z ORIGINAL ARTICLE The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven
More informationFecal Microbiota Transplantation
Protocol Fecal Microbiota Transplantation (20192) Medical Benefit Effective Date: 10/01/14 Next Review Date: 07/18 Preauthorization Yes Review Dates: 07/14, 07/15, 07/16, 07/17 Preauthorization is required.
More informationNew Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility
New Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility Gerald A. Capraro, Ph.D., D(ABMM) Director, Clinical Microbiology Carolinas Pathology Group Atrium
More informationClostridium difficile Essential information
Clostridium difficile Essential information Clostridium difficile Origins Clostridium difficile (C. diff) is a Gram positive, spore forming, anaerobic bacterium with a rod structure. It was first identified
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationClostridium difficile infections: Drug treatment re-evaluated
Clostridium difficile infections: Drug treatment re-evaluated Kimberly D. Leuthner, PharmD University Medical Center of Southern Nevada August 11, 2016 Random Fact: The human body has 10 13 human cells
More informationMarch 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments
March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE
More informationL infezione da Clostridium difficile (CDI) Quadri clinici e nuovi approcci terapeutici
L infezione da Clostridium difficile (CDI) Quadri clinici e nuovi approcci terapeutici Roberto Luzzati SC Malattie Infettive, AOU Trieste Presidente :Prof. Enzo Raise Clinical presentation of infection
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Fecal Microbiota Transplant MP-066-MD-DE Medical Management Provider Notice Date: 10/15/2018; 04/15/2018 Issue Date: 11/15/2018;
More informationClostridium difficile Infection (CDI)
18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through
More informationClinical Policy Bulletin: Fecal Bacteriotherapy
Clinical Policy Bulletin: Fecal Bacteriotherapy Number: 0844 Policy Aetna considers fecal bacteriotherapy medically necessary for persons with Clostridium difficile infection, with infection confirmed
More informationLearning Objectives. A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials. Fidaxomicin vs. Vancomycin. Outline 1/3/2012
Learning Objectives A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials Amy E. Lodolce, PharmD, BCPS Assistant Director, Drug Information Group UIC College of Pharmacy Describe the methods and
More informationSherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine
Sherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine Chief Scientific Officer, Optimer Pharmaceuticals, Inc. Conflicts: Chief Scientific Officer,
More informationAdvances in Gastrointestinal Pathogen Detection
Advances in Gastrointestinal Pathogen Detection Erin McElvania TeKippe, Ph.D., D(ABMM) Director of Clinical Microbiology Children s Health System, Assistant Professor of Pathology and Pediatrics UT Southwestern
More information